Positron Corporation Announces Its Transition to a Reporting SEC Company
Positron Corporation (OTC: POSC) announced on November 17, 2025 that it has become an SEC reporting company by filing a Form 10 containing required financial statements and disclosures.
The company will now file quarterly, annual, and current reports under the Securities Exchange Act of 1934, enhancing financial transparency, strengthening corporate governance, and positioning Positron to pursue an uplisting to a senior exchange. Management said the change supports broader institutional visibility and access to capital as Positron commercializes its PET-CT technologies, including a new 4D PET-CT system, and leverages an exclusive North American partnership with Neusoft Medical Systems.
Positron Corporation (OTC: POSC) ha annunciato il 17 novembre 2025 di essere diventata una società SEC reporting presentando un Form 10 contenente i bilanci e le comunicazioni richieste.
La società compilerà ora rapporti trimestrali, annuali e correnti ai sensi del Securities Exchange Act del 1934, aumentando trasparenza finanziaria, rafforzando governance aziendale e posizionando Positron per un uplisting su una borsa senior. Il management ha dichiarato che il cambiamento supporta una maggiore visibilità istituzionale e l’accesso al capitale mentre Positron commercializza le sue tecnologie PET-CT, tra cui un nuovo sistema PET-CT 4D, e sfrutta una partnership esclusiva in Nord America con Neusoft Medical Systems.
Positron Corporation (OTC: POSC) anunció el 17 de noviembre de 2025 que se ha convertido en una empresa que reporta a la SEC al presentar un Formulario 10 que contiene los estados financieros y las divulgaciones requeridas.
La compañía ahora presentará informes trimestrales, anuales y actuales conforme a la Securities Exchange Act de 1934, aumentando la transparencia financiera, fortaleciendo la gobernanza corporativa y posicionando a Positron para realizar un uplisting a una bolsa superior. La gerencia dijo que el cambio facilita una mayor visibilidad institucional y acceso al capital a medida que Positron comercializa sus tecnologías PET-CT, incluido un nuevo sistema PET-CT 4D, y aprovecha una asociación exclusiva en Norteamérica con Neusoft Medical Systems.
Positron Corporation (OTC: POSC)는 2025년 11월 17일에 필요한 재무제표와 공시를 포함한 Form 10을 제출하여 SEC 보고회사로 전환되었다고 발표했다.
이제 이 회사는 1934년 증권거래법에 따라 분기보고서, 연차보고서 및 현재보고서를 제출하게 되며, 재무 투명성을 강화하고 기업지배구조를 강화하며 포지트론이 상장 상향(상위 거래소로의 uplisting)를 추구하도록 위치를 정립한다. 경영진은 이번 변화가 포지트론이 PET-CT 기술 상용화로 자본에 대한 접근성과 제도적 가시성을 넓혀주며, 신규 4D PET-CT 시스템 및 북미 지역의 독점 파트너십인 Neusoft Medical Systems를 활용하는 데 도움이 된다고 말했다.
Positron Corporation (OTC : POSC) a annoncé le 17 novembre 2025 qu'elle est devenue une société soumise à des rapports SEC en déposant un formulaire 10 contenant les états financiers et les divulgations requis.
La société déposera désormais des rapports trimestriels, annuels et courants en vertu du Securities Exchange Act de 1934, ce qui renforcera la transparence financière, améliorera la gouvernance d'entreprise et positionnera Positron pour envisager un uplisting vers une bourse de premier ordre. La direction a déclaré que ce changement favorise une plus grande visibilité institutionnelle et l'accès au capital à mesure que Positron commercialise ses technologies PET-CT, notamment un nouveau système PET-CT 4D, et exploite un partenariat exclusif en Amérique du Nord avec Neusoft Medical Systems.
Positron Corporation (OTC: POSC) gab am 17. November 2025 bekannt, dass sie durch die Einreichung eines Form 10, das erforderliche Finanzberichte und Offenlegungen enthält, zu einem SEC-berichtenden Unternehmen geworden ist.
Das Unternehmen wird nun vierteljährliche, jährliche und aktuelle Berichte gemäß dem Securities Exchange Act von 1934 einreichen, was finanzielle Transparenz erhöht, Unternehmensführung stärkt und Positron die Möglichkeit gibt, einen Uplisting an eine Senior Exchange anzustreben. Das Management sagte, die Änderung unterstütze eine breitere institutionelle Sichtbarkeit und Zugang zu Kapital, während Positron seine PET-CT-Technologien, einschließlich eines neuen 4D-PET-CT-Systems, kommerzialisiert und eine exklusive Partnerschaft mit Neusoft Medical Systems in Nordamerika nutzt.
شركة بوسيتрон (OTC: POSC) أعلنت في 17 نوفمبر 2025 أنها أصبحت شركة تقارير لدى SEC من خلال تقديم نموذج 10 الذي يحتوي على البيانات المالية والإفصاحات المطلوبة.
سيقوم الشركة الآن بتقديم تقارير ربع سنوية وسنوية وتقارير حالية بموجب قانون البورصة لعام 1934، مما يعزز الشفافية المالية، ويعزز حوكمة الشركة، ويمهد لـإدراج أعلى إلى بورصة رائدة. وقالت الإدارة إن التغيير يدعم رؤية مؤسسية أوسع ووصولًا لرأس المال بينما تُسَوِّق Positron تقنياتها PET-CT، بما في ذلك نظام PET-CT 4D الجديد، وتستفيد من شراكة حصرية في أمريكا الشمالية مع Neusoft Medical Systems.
- SEC reporting status achieved on November 17, 2025
- Positions company for a possible uplist to a senior exchange
- Supports broader access to capital markets
- Exclusive North American partnership with Neusoft Medical Systems
- None.
Buffalo, NY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced that it has become a reporting company with the U.S Securities and Exchange Commission (SEC). The Company filed a Form 10 registration statement with the SEC containing all required financial statements and disclosures and is now subject to the reporting requirements of the Securities Exchange Act of 1934, as amended. The Company will now be filing its quarterly and annual reports with the SEC, along with current reports to provide updates on material events.
Becoming an SEC reporting company marks a significant milestone in Positron’s growth trajectory. The transition enhances the Company’s financial transparency, strengthens corporate governance, and positions Positron for broader institutional visibility as it advances plans to uplist to a senior exchange.
“This achievement reflects our commitment to transparency and to building a world-class company in molecular imaging,” said Adel Abdullah, CEO of Positron Corporation. “As Positron expands the commercialization of its PET-CT technologies, including our new 4D PET-CT system, our SEC reporting status provides investors, customers, and partners with the confidence that we operate with the highest standards of accountability.”
Positron’s enhanced reporting status comes at a time of accelerating demand for PET-CT imaging in cardiology and oncology. With its expanding product portfolio, exclusive North American partnership with Neusoft Medical Systems, and a fast-growing pipeline of system sales and service contracts, we believe the Company is strategically positioned to capture significant market share in the years ahead.
“We expect this milestone will broaden our access to capital markets and support Positron’s long-term growth objectives,” added Mr. Abdullah. “We look forward to continued execution as we bring high-performance, cost-effective molecular imaging solutions to practices and hospitals across the U.S. and internationally.”
About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's PET and PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Please visit the Company’s website at: www.positron.com
Forward-Looking Statements
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
info@skylineccg.com
FAQ
What did Positron (POSC) announce on November 17, 2025 about SEC reporting?
How does SEC reporting affect Positron (POSC) shareholders?
Will Positron (POSC) try to list on a senior exchange after SEC reporting?
What products and partnerships did Positron (POSC) highlight with the SEC transition?
Does SEC reporting improve Positron's (POSC) access to capital?
